

09/853409

Search results

Refine Search

Search Results -

Terms	Documents
L5 and (administer\$ or pharmaceut\$) near5 subcutaneous	191

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L13

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, June 18, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L13</u>	L5 and (administer\$ or pharmaceut\$) near5 subcutaneous	191	<u>L13</u>
<u>L12</u>	L6 and subcutaneous	167	<u>L12</u>
<u>L11</u>	L5 and subcutaneous	1441	<u>L11</u>
<u>L10</u>	L9 and AUG	56	<u>L10</u>
<u>L9</u>	(HCV or NANBH or hepatitis near C) near10 (antisense or complementary) and initiation near codon\$	74	<u>L9</u>
<u>L8</u>	L6 and gtgctcatggt?	0	<u>L8</u>
<u>L7</u>	L6 and gctcatggt	0	<u>L7</u>
<u>L6</u>	L5 and (antisense or complementary) near10 initiation near codon\$	183	<u>L6</u>
<u>L5</u>	(HCV or NANBH or hepatitis near C) and antisense	2393	<u>L5</u>
<u>L4</u>	L3	2	<u>L4</u>
<u>L3</u>	6284458 [pn]	2	<u>L3</u>
<u>L2</u>	6391542 [pn]	2	<u>L2</u>

L1 6174868 [pn]

2 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 74 of 74 returned.**

-
- ☐ 1. 20040116509. 11 Jun 02. 17 Jun 04. COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS. Chan Chun Kong, Laval, et al. 514/447; 549/63 A61K031/381.
-
- ☐ 2. 20040092730. 15 Aug 01. 13 May 04. Hepatitis C virus non-structural NS3/4A fusion gene. Sallberg, Matti. 536/23.72; 435/235.1 435/320.1 530/328 C07H021/04 F03D007/00 F04D015/00 F03B015/08 F04D027/00 C07K007/00 A61K038/04 F01D017/06 F01B025/06 C12N007/01 C12N015/63 C07K017/00 C12N015/74.
-
- ☐ 3. 20040091851. 12 Nov 02. 13 May 04. HCV peptide compositions. Houghton, Michael, et al. 435/5; 530/350 C12Q001/70 C07K014/02.
-
- ☐ 4. 20040073380. 08 Sep 03. 15 Apr 04. Structural targets in hepatitis c virus ires element. Puglisi, Joseph D.. 702/25; G06F019/00.
-
- ☐ 5. 20040049021. 04 Jun 03. 11 Mar 04. Compositions and mehtods for treatment of Hepatitis C virus-associated diseases. Anderson, Kevin P., et al. 536/23.1; 536/23.72 C07H021/02.
-
- ☐ 6. 20040033978. 09 Jun 03. 19 Feb 04. Compositions and methods for treatment of Hepatitis C virus-associated diseases. Anderson, Kevin P., et al. 514/44; 536/23.1 A61K048/00 C07H021/02.
-
- ☐ 7. 20040033977. 04 Jun 03. 19 Feb 04. Oligonucleotide modulation of cell adhesion. Bennett, C. Frank, et al. 514/44; 536/23.1 A61K048/00 C07H021/02.
-
- ☐ 8. 20040029278. 17 May 02. 12 Feb 04. Eukaryotic layered vector initiation systems. Dubensky, Thomas W. JR., et al. 435/456; 435/320.1 435/325 C12N015/861 C12N015/86.
-
- ☐ 9. 20040009938. 06 Feb 03. 15 Jan 04. Methods of enhancing renal uptake of oligonucleotides. Manoharan, Muthiah, et al. 514/44; 514/47 514/50 A61K048/00 A61K031/7076 A61K031/7072.
-
- ☐ 10. 20030232328. 14 Mar 03. 18 Dec 03. Method of detecting antibodies to HCV. Houghton, Michael, et al. 435/5; C12Q001/70.
-
- ☐ 11. 20030232035. 16 Jan 03. 18 Dec 03. Eukaryotic layered vector initiation systems. Dubensky, Thomas W. JR., et al. 424/93.2; 435/320.1 435/325 435/456 435/6 800/8 A01K067/00 C12Q001/68 A61K048/00 C12P021/02 C12N005/06 C12N015/86.
-
- ☐ 12. 20030224353. 24 Apr 03. 04 Dec 03. Antisense antiviral agent and method for treating ssRNA viral infection. Stein, David A., et al. 435/5; 514/81 514/90 544/81 544/82 C12Q001/70 A61K048/00 C07F009/6533.
-
- ☐ 13. 20030206919. 26 Nov 02. 06 Nov 03. Hepatitis C virus codon optimized non-structural NS3/4A fusion gene. Sallberg, Matti. 424/189.1; 424/93.2 435/320.1 435/325 435/69.3 514/44 530/350 536/23.72 A61K048/00 C07H021/04 C12P021/02 C12N005/06 C07K014/02 A61K039/29 A61K031/70 A01N043/04 C12N015/09 A01N063/00 C12N015/00 C12N015/63 C12N015/70 C12N015/74

C12N005/00 C12N005/02 C07K001/00 C07K014/00 C07K017/00.

☐ 14. 20030199503. 20 Dec 02. 23 Oct 03. Compounds and methods for the treatment of prevention of flavivirus infections. Kong, Laval Chan Chun, et al. 514/235.5; 514/365 514/44 544/133 548/201 A61K048/00 C07D417/02 A61K031/5377 A61K031/426 C07D277/56.

☐ 15. 20030171335. 16 Oct 02. 11 Sep 03. Antisense antiviral agent and method for treating ssRNA viral infection. Stein, David A., et al. 514/81; 514/87 544/81 A61K031/675 C07F009/6533 A61K048/00.

☐ 16. 20030171313. 11 May 01. 11 Sep 03. Compositions and methods for treatment of hepatitis C virus-associated diseases. Anderson, Kevin P., et al. 514/44; 424/85.5 536/23.72 A61K048/00 A61K038/21 C07H021/04.

☐ 17. 20030162167. 25 Jul 96. 28 Aug 03. METHOD OF DETECTING ANTIBODIES TO HCV. HOUGHTON, MICHAEL, et al. 435/5; C12Q001/70 G01N033/53.

☐ 18. 20030125541. 27 Sep 02. 03 Jul 03. Replication competent hepatitis C virus and methods of use. Lemon, Stanley M., et al. 536/23.72; 435/235.1 435/5 435/6 536/23.1 C12Q001/70 C12N007/00 C12Q001/68 C07H021/02 C07H021/04 C12N007/01.

☐ 19. 20030125241. 17 May 02. 03 Jul 03. Therapeutic uses of LNA-modified oligonucleotides in infectious diseases. Wissenbach, Margit, et al. 514/8; 514/44 A61K048/00.

☐ 20. 20030073080. 27 Jul 01. 17 Apr 03. Functional DNA clone for hepatitis C virus (HCV) and uses thereof. Rice, Charles M., et al. 435/6; 424/228.1 435/325 435/5 536/23.72 C12Q001/70 C12Q001/68 C07H021/04 A61K039/29 C12N005/06.

☐ 21. 20030064360. 05 Jun 01. 03 Apr 03. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents. Maertens, Geert, et al. 435/5; 435/235.1 435/320.1 435/325 435/456 536/23.72 C12Q001/70 C07H021/04 C12N007/00 C12P021/02 C12N005/06 C12N015/86.

☐ 22. 20030032005. 12 Jun 01. 13 Feb 03. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents. Maertens, Geert, et al. 435/5; 424/231.1 435/235.1 536/23.72 C12Q001/70 C07H021/04 A61K039/245 C12N007/00.

☐ 23. 20030028010. 28 Nov 01. 06 Feb 03. Functional DNA clone for hepatitis C virus (HCV) and uses thereof. Rice, Charles M. III, et al. 536/23.72; 424/186.1 435/235.1 A61K039/12 C07H021/04 C12N007/01.

☐ 24. 20030008282. 06 Jun 01. 09 Jan 03. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. Capon, Daniel J., et al. 435/6; 435/320.1 435/5 C12Q001/68 C12Q001/70 C12N015/869.

☐ 25. 20030008274. 06 Jul 01. 09 Jan 03. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents. Maertens, Geert, et al. 435/5; 424/189.1 514/44 536/23.72 C12Q001/70 C07H021/04 A61K039/29 A61K048/00.

☐ 26. 20020183508. 09 May 01. 05 Dec 02. Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents. Maertens, Geert, et al. 536/23.72; 435/235.1 435/5 C12Q001/70 C07H021/04 C12N007/00.

-
- ☐ 27. 20020136740. 15 Aug 01. 26 Sep 02. Vaccines containing ribavirin and methods of use thereof. Sallberg, Matti, et al. 424/225.1; 424/204.1 424/227.1 424/93.2 435/5 435/91.1 435/91.33 514/43 514/44 A61K048/00 A61K039/12 A61K031/7056 C12Q001/70 A61K031/70 A01N043/04 C12P019/34 A01N063/00 A61K039/29.
-
- ☐ 28. 20020102540. 26 Jan 99. 01 Aug 02. FUNCTIONAL DNA CLONE FOR HEPATITIS C VIRUS (HCV) AND USES THEREOF. RICE, CHARLES M., et al. 435/6; C12Q001/68.
-
- ☐ 29. 20020102534. 26 Sep 01. 01 Aug 02. Exhaustive analysis of viral protein interactions by two-hybrid screens and selection of correctly folded viral interacting polypeptides. LeGrain, Pierre, et al. 435/5; 435/235.1 435/6 435/7.1 C12Q001/70 C12Q001/68 G01N033/53 C12N007/00.
-
- ☐ 30. 6673912. 11 Apr 02; 06 Jan 04. 2'-O-aminoethyloxyethyl-modified oligonucleotides. Manoharan; Muthiah, et al. 536/23.1; 536/24.3 536/25.3 536/26.6. C07H021/00 C07H021/02 C07H021/04.
-
- ☐ 31. 6608191. 18 Oct 00; 19 Aug 03. Compositions and methods for treatment of hepatitis C virus-associated diseases. Anderson; Kevin P., et al. 536/24.5; 536/23.1. C07H021/04 C07H021/02.
-
- ☐ 32. 6600032. 06 Aug 99; 29 Jul 03. 2'-O-aminoethyloxyethyl-modified oligonucleotides. Manoharan; Muthiah, et al. 536/26.6; 435/6. C07H021/04.
-
- ☐ 33. 6562570. 28 Mar 00; 13 May 03. Method for identifying accessible binding sites on RNA. Rossi; John J., et al. 435/6; 435/91.1 435/91.2. C12Q001/68 C12P019/34.
-
- ☐ 34. 6433159. 17 Mar 97; 13 Aug 02. Compositions and methods for treatment of Hepatitis C virus associated diseases. Anderson; Kevin P.. 536/24.5; 536/23.1. C07H021/04.
-
- ☐ 35. 6423489. 30 May 95; 23 Jul 02. Compositions and methods for treatment of Hepatitis C virus-associated diseases. Anderson; Kevin P., et al. 435/6; 435/325 435/366 536/23.1 536/24.5. C12Q001/68 C07H021/04 C12N015/85.
-
- ☐ 36. 6392028. 04 Mar 98; 21 May 02. Functional DNA clone for hepatitis C virus (HCV) and uses thereof. Rice, III; Charles Moen, et al. 536/23.72; 435/363 435/364 435/366 435/370. C07H021/02 C07H021/04 C12N005/16 C12N005/22.
-
- ☐ 37. 6391542. 17 May 96; 21 May 02. Compositions and methods for treatment of Hepatitis C virus-associated diseases. Anderson; Kevin P., et al. 435/6; 435/325 435/375 435/91.1 536/23.1 536/24.5. C12Q001/68 C07H021/04 C12N015/85 C12P019/34.
-
- ☐ 38. 6376236. 22 Jan 99; 23 Apr 02. Recombinant alphavirus particles. Dubensky, Jr.; Thomas W., et al. 435/320.1; C12N015/63.
-
- ☐ 39. 6346375. 14 Mar 95; 12 Feb 02. NANBV diagnostics and vaccines. Chien; David Y.. 435/5; 424/189.1 424/228.1 530/324 530/325 530/326 530/327 530/350. C12Q001/70 C07K014/18.
-
- ☐ 40. 6342372. 08 Jul 99; 29 Jan 02. Eukaryotic layered vector initiation systems for production of recombinant proteins. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/455 536/23.2 536/23.72 536/24.1. C12N005/16 C12N015/11 C12N015/33.
-

- ☐ 41. 6284458. 09 Mar 95; 04 Sep 01. Compositions and methods for treatment of hepatitis C virus-associated diseases. Anderson; Kevin P., et al. 435/6; 435/325 435/366 536/23.1 536/24.5. C12Q001/68 C07H021/04 C12N015/85.
-
- ☐ 42. 6277982. 20 Aug 99; 21 Aug 01. Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates. Fraser; Allister S., et al. 536/25.3; 536/23.1 536/25.31. C07H021/04 C07H021/00.
-
- ☐ 43. 6271358. 27 Jul 98; 07 Aug 01. RNA targeted 2'-modified oligonucleotides that are conformationally preorganized. Manoharan; Muthiah, et al. 536/23.1; 435/6 536/26.23 536/26.26 536/26.8 536/26.9 536/27.6 536/27.8 536/27.81 536/28.5 536/28.53. C07H021/00 C07H021/02 C07H021/04.
-
- ☐ 44. 6271210. 05 Oct 99; 07 Aug 01. Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer. Sivaraman; Vimala S., et al. 514/44; 435/320.1 435/325 435/366 536/24.5. A61K048/00 C07H021/04 C12N015/85 C12Q001/68.
-
- ☐ 45. 6242187. 10 Aug 99; 05 Jun 01. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. Capon; Daniel J., et al. 435/6; 435/320.1 435/369 435/370. C12Q001/68.
-
- ☐ 46. 6235888. 05 Jun 97; 22 May 01. Hepatitis C virus vaccine. Pachuk; Catherine J., et al. 536/23.72; 435/320.1 536/23.1 536/23.7. C07H021/04 C12N015/63.
-
- ☐ 47. 6174868. 10 Dec 97; 16 Jan 01. Compositions and methods for treatment of hepatitis C virus-associated diseases. Anderson; Kevin P., et al. 514/44; 536/23.1 536/24.5. A61K031/711 A61K031/7115 A61K031/7125.
-
- ☐ 48. 6171782. 15 May 95; 09 Jan 01. Antibody compositions to HCV and uses thereof. Houghton; Michael, et al. 435/5; 424/130.1 424/139.1 424/161.1 435/7.1 435/70.21 435/810 435/975 436/513 436/531. C12Q001/70 G01N033/53 A61K039/395 A61K039/42.
-
- ☐ 49. 6150087. 18 May 95; 21 Nov 00. NANBV diagnostics and vaccines. Chien; David Y., et al. 435/5; 424/189.1 424/228.1 530/324 530/325 530/326 530/327 530/328 530/329 530/350. C12Q001/70 C07K014/18.
-
- ☐ 50. 6127116. 04 Mar 97; 03 Oct 00. Functional DNA clone for hepatitis C virus (HCV) and uses thereof. Rice; Charles M., et al. 435/6; 435/320.1 435/325 536/23.7 536/24.1 536/24.3 536/24.5. C07H021/02 C07H021/04 C12N005/10 C12N015/63.
-
- ☐ 51. 6100068. 29 Jul 98; 08 Aug 00. Method of protein production using mitochondrial translation system. Paik; Kye-Hyung. 435/69.3; 435/69.1 435/70.1 435/70.3. C12N015/09.
-
- ☐ 52. 6096541. 15 May 95; 01 Aug 00. Cell culture systems for HCV. Houghton; Michael, et al. 435/370; 424/9.2 424/93.1 435/325 435/363 435/366 435/455 435/5 435/7.1. C12Q001/70 G01N033/53 C12N005/08.
-
- ☐ 53. 6074816. 16 Sep 94; 13 Jun 00. NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus. Houghton; Michael, et al. 435/5; 435/252.3 435/320.1 435/325 435/6 536/23.72 536/24.32 536/24.33. C12Q001/70 C12Q001/68 C12N015/40.
-

-
- ☐ 54. 6057093. 12 May 95; 02 May 00. Methods and compositions for controlling translation of HCV proteins. Han; Jang H., et al. 435/5; 435/6 435/69.1 536/24.1. C12Q001/70 C12Q001/68 C12N015/67.
-
- ☐ 55. 6043352. 07 Aug 98; 28 Mar 00. 2'-O-Dimethylaminoethoxyethyl-modified oligonucleotides. Manoharan; Muthiah, et al. 536/24.2; 435/6 536/24.5 536/26.6. C07H021/04.
-
- ☐ 56. 6027729. 15 May 95; 22 Feb 00. NANBV Diagnostics and vaccines. Houghton; Michael, et al. 424/228.1; 424/186.1 424/189.1 424/204.1 435/5 435/6 530/300 530/350. C12Q001/70 A61K039/12 A61K039/29.
-
- ☐ 57. 6025341. 12 May 97; 15 Feb 00. Chimeric hepatitis B/hepatitis C virus vaccine. Wands; Jack R., et al. 514/44; 530/350 536/23.1. C12N015/11 C07K014/00 A61K048/00.
-
- ☐ 58. 6015694. 16 Sep 97; 18 Jan 00. Method for stimulating an immune response utilizing recombinant alphavirus particles. Dubensky, Jr.; Thomas W., et al. 435/69.3; 424/199.1 424/204.1 424/228.1 424/234.1 424/265.1 424/274.1 424/277.1 536/23.5 536/23.7 536/23.72. C12P021/06.
-
- ☐ 59. 6015686. 15 Mar 95; 18 Jan 00. Eukaryotic layered vector initiation systems. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/320.1 435/325 435/410 435/455 435/456 536/23.5 536/23.72 536/24.1. C12P021/02 C12N015/00 C12N015/63 C12N015/11.
-
- ☐ 60. 6007991. 12 Aug 97; 28 Dec 99. Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer. Sivaraman; Vimala S., et al. 435/6; 435/325 514/44 536/24.5. C12Q001/68 C12N015/85 A61K048/00 C07H021/04.
-
- ☐ 61. 6001990. 07 Jun 95; 14 Dec 99. Antisense inhibition of hepatitis C virus. Wands; Jack R., et al. 536/24.5; 435/320.1. C07H021/04 C12N015/00.
-
- ☐ 62. 5922857. 12 May 95; 13 Jul 99. Methods and compositions for controlling translation of HCV proteins. Han; Jang H., et al. 536/24.1; 536/24.5. C07H021/02 C07H021/04.
-
- ☐ 63. 5843723. 30 Oct 96; 01 Dec 98. Alphavirus vector constructs. Dubensky, Jr.; Thomas W., et al. 435/69.3; 435/235.1 435/320.1 435/325. C12P021/02 C12N015/63 C12N005/10.
-
- ☐ 64. 5843639. 07 Jun 95; 01 Dec 98. Hepatitis C virus epitopes. Reyes; Gregory R., et al. 435/5; 530/350. C12Q001/70 C07K014/18.
-
- ☐ 65. 5843636. 17 Mar 95; 01 Dec 98. Hepatitis C virus epitopes. Reyes; Gregory R., et al. 435/5; 435/69.3 530/350 536/23.72. C12Q001/70 C12P021/06 C07H017/00.
-
- ☐ 66. 5814482. 30 Oct 96; 29 Sep 98. Eukaryotic layered vector initiation systems. Dubensky, Jr.; Thomas W., et al. 435/69.3; 435/320.1 536/23.1 536/24.1. C12P021/00 C12N015/86 C07H021/04.
-
- ☐ 67. 5789245. 30 Oct 96; 04 Aug 98. Alphavirus structural protein expression cassettes. Dubensky, Jr.; Thomas W., et al. 435/320.1; 435/325 435/69.1 536/23.72. C12N015/63 C12N015/40 C12N005/10 C12P021/02.
-
- ☐ 68. 5698390. 15 Sep 94; 16 Dec 97. Hepatitis C immunoassays. Houghton; Michael, et al. 435/5; 436/518 436/820. C12Q001/70 G01N033/576.
-

-
- ☐ 69. 5538865. 19 Jan 94; 23 Jul 96. Hepatitis C virus epitopes. Reyes; Gregory, et al. 435/69.3; 435/5 530/350. C12P021/06 C12Q001/70 C07K014/18.
-
- ☐ 70. 5443965. 05 Apr 91; 22 Aug 95. Hepatitis C virus epitopes. Reyes; Gregory R., et al. 435/69.3; 424/189.1 435/252.8 435/5 536/23.72. C12P021/06 C12Q001/70 A61K039/29 C07H017/00.
-
- ☐ 71. 5436318. 20 Mar 92; 25 Jul 95. Hepatitis C virus epitopes. Reyes; Gregory, et al. 530/350; 435/235.1 435/320.1 435/5 435/69.7 530/826 536/23.72. C07K015/04 C12Q001/70 C12P021/06 C07H017/00.
-
- ☐ 72. 5350671. 09 Aug 93; 27 Sep 94. HCV immunoassays employing C domain antigens. Houghton; Michael, et al. 435/5; 435/6 435/975 436/512 436/518 530/300 530/326 530/327 530/328 530/812 530/826 930/220 930/223. C12G001/70 C12G001/68 A61K037/02 G01N033/543.
-
- ☐ 73. EP 662157B. Anti:sense oligo:nucleotide(s) complementary to hepatitis C viral genome - useful for inhibiting HCV replication, to treat related diseases. ANDERSON, K P, et al. A61K031/70 A61K031/725 A61K048/00 C07H021/00 C07H021/02 C07H021/04 C07K015/00 C12N005/10 C12N015/09 C12N015/11 C12N015/51 C12N015/85 C12P021/02 C12Q001/68 C12Q001/70 G01N033/53 G01N033/576.
-
- ☐ 74. WO 9212992A. Basic structural immunogenic peptide(s) having epitope(s) for HCV - useful as vaccines against HCV infection; also for diagnosis of HCV and auto:immune liver disease. BAROUDY, B M, et al. A61K039/29 C07K007/08 C07K013/00 C12N001/21 C12N015/11 C12N015/40 C12P021/08 C12Q001/68 C12Q001/70 G01N033/576 G01N033/577.
-

[Generate Collection](#)[Print](#)

Terms	Documents
(HCV or NANBH or hepatitis near C) near10 (antisense or complementary) and initiation near codon\$	74

[Prev Page](#)[Next Page](#)[Go to Doc#](#)




Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Friday
Date: 6/18/2004

Time: 11:19:52

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)